Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with Multiple Sclerosis.Hepatology. 2020 Jun 24 [Online ahead of print]Hep
Increased use of novel immunomodulatory agents has led to emerging forms of drug-induced liver injury. Alemtuzumab is a recombinant, humanized monoclonal antibody against CD52, which is present on T cells, B cells, monocytes and natural killer cells. A single dose results in a depletion of the entire lymphocyte population followed by varied kinetics in the recovery of each cell type. Alemtuzumab has been approved as an immune reconstitution therapy in relapsing and remitting multiple sclerosis (RRMS). Since its approval, cases of acute hepatitis have been documented but reports of delayed-onset immune-mediated hepatitis with recurrent episodes of liver failure following treatment with alemtuzumab have not been published.